GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Noul Co Ltd (XKRX:376930) » Definitions » Debt-to-EBITDA

Noul Co (XKRX:376930) Debt-to-EBITDA : -0.50 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Noul Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Noul Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩2,961 Mil. Noul Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩4,839 Mil. Noul Co's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩-15,569 Mil. Noul Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.50.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Noul Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:376930' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.92   Med: -0.45   Max: -0.13
Current: -0.52

During the past 5 years, the highest Debt-to-EBITDA Ratio of Noul Co was -0.13. The lowest was -0.92. And the median was -0.45.

XKRX:376930's Debt-to-EBITDA is ranked worse than
100% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.915 vs XKRX:376930: -0.52

Noul Co Debt-to-EBITDA Historical Data

The historical data trend for Noul Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noul Co Debt-to-EBITDA Chart

Noul Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.13 -0.40 -0.45 -0.92 -0.56

Noul Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 -0.73 -0.77 -0.40 -0.50

Competitive Comparison of Noul Co's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Noul Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Noul Co's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Noul Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Noul Co's Debt-to-EBITDA falls into.



Noul Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Noul Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2961.483 + 4838.573) / -13981.1
=-0.56

Noul Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2961.483 + 4838.573) / -15568.78
=-0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Noul Co  (XKRX:376930) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Noul Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Noul Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Noul Co (XKRX:376930) Business Description

Traded in Other Exchanges
N/A
Address
B-10F, 338, Gwanggyojungang-ro, Suji-gu, Gyeonggi-do, Yongin-si, KOR, 16942
Noul Co Ltd provides solutions for chronic and systemic problems in healthcare. The company's miLab is an all-in-one, fully-automated device which can process sample preparation and AI diagnostic in one workflow. It integrates technologies from computer vision AI, bio, hardware, and software engineering.

Noul Co (XKRX:376930) Headlines

No Headlines